Mazdutide peptide is a synthetic, acylated analogue of oxyntomodulin studied for coordinated activation of the GLP-1 and glucagon receptors.
Also known as IBI362 and LY3305677, it is investigated across receptor pharmacology, metabolic signalling, glucose regulation and energy-balance research.
Randomised Phase 2 and Phase 3 trials have also evaluated pharmaceutical formulations of mazdutide, and the compound has received regulatory approval in China. These clinical findings describe specific pharmaceutical products and study populations and should not be assumed to apply to separately supplied laboratory research materials.
This guide reviews mazdutide mechanism, experimental evidence and current research limitations. Australia Peptide Sciences materials are supplied strictly for laboratory and scientific research and are not intended for human or veterinary administration.
What Is Mazdutide Peptide?
Mazdutide is a long-acting, acylated oxyntomodulin analogue designed to activate both GLP-1R and GCGR.
As a dual agonist, it targets both receptors through a single molecule rather than a mixture of separate peptides.
| Feature | Research summary |
| Alternative identifiers | IBI362 and LY3305677 |
| Molecular category | Synthetic, acylated peptide analogue |
| Biological reference | Oxyntomodulin |
| Primary receptor targets | GLP-1R and GCGR |
| Research classification | Dual-receptor co-agonist |
| Common study areas | Receptor pharmacology, metabolic signalling, glucose regulation and energy balance |
| Evidence types | Cellular assays, animal models and human clinical trials |
Research formulations, clinical-trial products and laboratory materials may use the same compound name, but this does not make them equivalent in identity, quality or supporting evidence.
Mazdutide Mechanism: How GLP-1R and GCGR Signalling Interact
The mazdutide mechanism involves coordinated activation of GLP-1R and GCGR, two class B G protein-coupled receptors that commonly signal through cAMP. This dual-receptor profile places mazdutide within the broader field of GLP-1 peptide research, while its glucagon receptor activity requires additional receptor-specific controls.
1. GLP-1 Receptor Activity
GLP-1R activation is studied in relation to glucose-dependent insulin secretion, appetite signalling and gastric emptying. Cellular cAMP measurements confirm receptor signalling, while evidence of whole-body effects comes from suitable preclinical or human studies.
2. Glucagon Receptor Activity
GCGR activity is associated with hepatic glucose production, lipid oxidation, amino-acid metabolism, and energy expenditure. Because glucagon signalling can also increase hepatic glucose output, its effects must be interpreted alongside GLP-1R activity and the conditions of the study.
3. Why Co-Agonism Requires Better Controls
In GLP-1 glucagon research, a measured response may result from GLP-1R, GCGR, or their combined activity. Receptor-selective agonists, antagonists, knockout models, and single-receptor cell lines can identify the pathway responsible for the observed response.
Synergy can be established only when the two pathways are tested individually under matched experimental conditions.
This distinction is especially important when comparing dual- and triple-receptor compounds. Researchers can review our Retatrutide Triple Agonist guide for an example involving GLP-1R, GIPR and GCGR activity within the same research compound.
Designing Mazdutide Peptide Research
Mazdutide peptide research begins with a clearly defined receptor, model, exposure period, and endpoint. Appropriate controls should distinguish receptor activation from downstream biological effects.
1. Receptor Pharmacology
GLP-1R- or GCGR-expressing cells can be used to measure binding, cAMP activity, EC50, Emax, and signalling duration. Separate receptor systems are valuable in dual agonist research because they reveal whether one receptor dominates the response.
2. Functional and Preclinical Models
Cellular and animal models can assess metabolic responses, but species differences limit their relevance to humans.
| Research question | Suitable model | Measurement | Essential control |
| Does the material activate GLP-1R? | GLP-1R-expressing cells | cAMP response | GLP-1R reference agonist |
| Does it activate GCGR? | GCGR-expressing cells | Receptor activation | GCGR reference agonist |
| Is the response receptor-dependent? | Receptor-null system | Loss or blockade of response | Selective antagonist |
Experimental design should also account for compound concentration, exposure duration and molar equivalence. Researchers performing laboratory concentration calculations can use the Peptide Calculator as a mathematical research tool.
How to Assess Mazdutide Identity, Purity and Experimental Reproducibility
Before a mazdutide research compound enters an experiment, researchers should confirm its identity and review batch-specific analytical documentation. The same principle applies to related compounds such as Tirzepatide peptide, because a product name alone does not establish identity, purity, concentration or experimental suitability.
Key checks include:
- Molecular identity and chromatographic purity
- Peptide content and relevant residual components
- Storage, stability and batch-traceability records
- Preparation and freeze-thaw history
HPLC can support purity assessment, while mass spectrometry can confirm molecular identity. Neither establishes biological potency, sterility, clinical safety, or equivalence to a clinical-trial formulation.
Reliable results also require verified concentrations, suitable controls, biological replicates, and predefined analysis rules.
For more detail on these quality variables, see our Peptide Purity Explained guide.
View Certificates of Analysis for Research Materials
Mazdutide Research Evidence
Mazdutide research spans receptor pharmacology, preclinical models and Phase 1, 2 and 3 clinical trials. Each evidence level answers a different question, so mechanistic, animal and clinical findings should remain clearly separated when drawing research conclusions.
1. Early and Phase 2 Studies
Early human studies assessed pharmacokinetics, tolerability, and preliminary metabolic effects. Phase 2 trials in Chinese adults with overweight, obesity or type 2 diabetes reported changes in body weight, glucose control and metabolic markers. Their limited duration and population scope restricted broader conclusions.
2. Phase 3 Programmes
GLORY-1 examined body-weight and metabolic outcomes over 48 weeks, while DREAMS-1 and DREAMS-2 evaluated glycaemic outcomes in adults with type 2 diabetes.
In the GLORY-2 randomised trial, 461 Chinese adults with obesity were studied for 60 weeks. Mean body-weight change was −16.65% with mazdutide and −1.50% with placebo. Vomiting, nausea and diarrhoea were the most frequently reported adverse events. These findings apply to the controlled trial population and do not guarantee equivalent outcomes elsewhere.
| Evidence stage | Main purpose | Typical endpoints | Key limitation |
| Cellular studies | Confirm receptor activity | Binding, cAMP, EC50 and Emax | Limited whole-body relevance |
| Animal studies | Assess physiological responses | Glucose, food intake and body composition | Species differences |
| Phase 1 | Assess exposure and tolerability | Pharmacokinetics and adverse events | Small, short studies |
| Phase 2 | Identify clinical signals | Body weight, HbA1c and metabolic markers | Limited duration and population |
| Phase 3 | Confirm efficacy and safety | Predefined clinical endpoints | Long-term and wider-population questions remain |
Evidence on mazdutide peptide pharmacology supports detailed scientific discussion, but clinical outcomes must remain separate from preclinical findings, mechanistic hypotheses, and company announcements.
These figures describe the tested pharmaceutical formulation, dose, protocol and Chinese study population. They should not be treated as expected outcomes for other populations or as evidence about separately supplied research materials.
Clinical percentages should therefore remain linked to their original study design. Laboratory studies answer different questions, including receptor activation, signalling strength, concentration-response relationships and material stability.
Explore Mazdutide 10mg for Laboratory Research Only
What Outcomes Does Mazdutide Research Measure?
1. Glucose Regulation and Insulin Signalling
Clinical studies have assessed HbA1c, fasting glucose and related glycaemic outcomes. These findings reflect the combined receptor activity, pharmaceutical formulation and trial conditions rather than GLP-1R activity alone. They should be interpreted as clinical endpoints rather than laboratory measures of receptor activity.
2. Energy Expenditure and Body Composition
GCGR activity supports research into energy expenditure, lipid oxidation and substrate utilisation. Body-weight change alone cannot distinguish fat mass, lean tissue and fluid changes, so research questions involving body composition require appropriate direct measurements.
3. Liver Fat and Lipid Metabolism
Human studies have reported changes in liver fat and related biomarkers. However, reduced liver fat on imaging does not confirm improvement in inflammation or fibrosis. Confirming those changes requires validated biomarkers, histology, or longer follow-up.
4. Renal and Cardiovascular Markers
Trials have assessed blood pressure, lipids, estimated glomerular filtration rate, and urinary albumin-to-creatinine ratio. These are surrogate markers, not evidence of fewer cardiovascular or kidney events. Until dedicated outcome trials are completed, they should not be interpreted as reductions in clinical event rates.
5. Emerging Neurological Questions
A 2025 preclinical study examined cognitive and neuronal outcomes in diabetic mice. The study was limited to an animal model and provides no evidence of neuroprotective effects in humans.
The video below reviews findings from the preclinical animal study on mazdutide’s potential neurological effects:
How Mazdutide Differs From Other Metabolic Research Compounds
Metabolic compounds may affect similar endpoints while acting through different molecular targets. These differences determine the controls, assays, and research questions appropriate to each compound.
| Compound | Principal target or origin | Research distinction |
| Mazdutide | GLP-1R and GCGR | Dual GLP-1 and glucagon receptor agonism |
| Tirzepatide | GIPR and GLP-1R | Dual incretin receptor agonism |
| Retatrutide | GIPR, GLP-1R and GCGR | Triple-receptor agonism |
| AOD-9604 | Growth hormone-derived fragment | Does not use incretin or glucagon co-agonism |
The guide to Tirzepatide peptide examines its combined GIPR and GLP-1R activity. Tirzepatide findings cannot replace mazdutide controls because the compounds differ in their secondary receptor targets.
Similarly, the AOD-9604 research guide examines a growth-hormone-derived fragment with a distinct molecular origin and research pathway.
Results from separate trials should not be ranked directly because populations, durations, formulations, and statistical methods differ. Reliable comparisons require adequately powered head-to-head studies.
For structured side-by-side analyses of research compounds, browse our Peptide Comparison Guides.
Mazdutide Clinical Safety Evidence and Research Gaps
Clinical trials of pharmaceutical mazdutide formulations most frequently reported gastrointestinal adverse events including nausea, vomiting and diarrhoea, with frequency varying according to dose, population and study design. Investigators also monitored laboratory measurements, vital signs and treatment discontinuation.
These findings apply to characterised pharmaceutical formulations evaluated under controlled clinical protocols. They do not establish the safety, sterility, identity or equivalence of separately supplied laboratory research materials.
Questions requiring further research include:
- Long-term cardiovascular and renal outcomes
- Effects of sustained GCGR activation on amino-acid metabolism
- Validated changes in fat and lean mass
- Outcomes across diverse populations and after discontinuation
- Equivalence between clinical formulations and research materials
Describing a compound only as “well tolerated” provides insufficient context for scientific interpretation. Safety reporting should remain linked to the study population, formulation, exposure conditions, comparator, duration and measured adverse events.
Future Directions for Mazdutide Research
Future clinical research should examine cardiovascular and renal outcomes, body-composition maintenance and post-treatment changes. Laboratory research can separately investigate receptor balance, signalling bias, concentration-response relationships and tissue-specific pathways.
Mazdutide Peptide Research: Key Findings and Limitations
Mazdutide peptide combines GLP-1R and GCGR activity within one engineered molecule, making receptor balance central to both its scientific interest and experimental complexity.
Clinical trials have expanded the evidence base for pharmaceutical mazdutide formulations, but these findings remain tied to specific populations, protocols and products. Laboratory research requires independently verified materials, receptor-specific controls, defined concentrations and clear separation between cellular, animal and clinical evidence.
For additional compound-specific laboratory information, browse our Research Peptide Guides.
View Certificates of Analysis for Research Materials
FAQs About Mazdutide Peptide
What does the peptide mazdutide do?
Mazdutide activates GLP-1 and glucagon receptors. In research, this dual-receptor activity is investigated through receptor signalling, metabolic pathways, glucose-related endpoints, energy balance and other model-specific measurements.
How does mazdutide differ from semaglutide?
Mazdutide activates both GLP-1R and GCGR, whereas semaglutide primarily activates GLP-1R. This creates different receptor profiles and requires different experimental controls when the compounds are compared.
Is long-term mazdutide safety fully established?
Long-term clinical evidence remains more limited than shorter-duration trial data. Published safety findings apply to the pharmaceutical formulations and populations studied and cannot establish the safety of separately supplied laboratory materials.
Is mazdutide better than retatrutide?
No direct head-to-head evidence establishes overall superiority. Mazdutide activates GLP-1R and GCGR, while retatrutide also includes GIPR activity. Their different receptor profiles mean comparisons should be made endpoint by endpoint and within appropriately designed studies.
What adverse events have been reported in mazdutide clinical trials?
Clinical trials of pharmaceutical mazdutide formulations have most commonly reported gastrointestinal events including nausea, vomiting and diarrhoea. These observations describe the tested clinical products and do not establish a safety profile for research materials.
Can mazdutide and tirzepatide trial results be compared directly?
Not reliably without an appropriately designed head-to-head study. Separate trials use different populations, doses, durations, formulations and statistical methods, so headline percentages should not be treated as a direct ranking.
What is the commercial name for mazdutide?
Mazdutide has been marketed in China under the commercial name Xinermei. This commercial pharmaceutical product should not be treated as equivalent to laboratory research materials carrying the same compound name.
Is mazdutide effective for weight loss?
Clinical trials have reported body-weight changes with pharmaceutical mazdutide formulations. For example, GLORY-2 reported a mean body-weight change of −16.65% in the studied mazdutide group versus −1.50% with placebo after 60 weeks. These figures apply to the specific clinical trial and should not be extrapolated to laboratory research materials.
Is mazdutide available for laboratory research?
Australia Peptide Sciences lists Mazdutide 10mg as a laboratory research material. It is supplied for research purposes only and is not intended for human consumption or therapeutic use.
Can mazdutide and survodutide outcomes be compared directly?
No reliable direct difference has been established without a head-to-head randomised study. Cross-trial comparisons are limited by differences in population, dose, duration, formulation and analysis methods.
References
- Ji L, et al. IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose Phase 1b study. EClinicalMedicine. 2021;39:101088. https://doi.org/10.1016/j.eclinm.2021.101088
- Jiang H, et al. A Phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nature Communications. 2022;13:3613. https://doi.org/10.1038/s41467-022-31328-x
- Ji L, et al. A Phase 2 randomised controlled trial of Mazdutide in Chinese adults with overweight or obesity. Nature Communications. 2023;14:8289. https://doi.org/10.1038/s41467-023-44067-4
- Zhang B, et al. Efficacy and safety of Mazdutide in Chinese patients with type 2 diabetes: a randomised, double-blind, placebo-controlled Phase 2 trial. Diabetes Care. 2024;47(1):160–168. https://doi.org/10.2337/dc23-1287
- Ji L, et al. Once-weekly Mazdutide in Chinese adults with obesity or overweight. New England Journal of Medicine. 2025;392:2215–2225. https://doi.org/10.1056/NEJMoa2411528
- Shirley M. Mazdutide: First Approval. Drugs. 2025;85:1621–1627. https://doi.org/10.1007/s40265-025-02249-y
- Zhu D, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes. Nature. 2026;652:174–180. https://doi.org/10.1038/s41586-025-10026-w
- Guo L, et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature. 2026;652:181–188. https://doi.org/10.1038/s41586-025-10031-z
- Gao L, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026;336(5):377–388. https://doi.org/10.1001/jama.2026.8142
